145 related articles for article (PubMed ID: 1902597)
1. Physical exercise induces enhancement of urokinase-type plasminogen activator (u-PA) levels in plasma.
Dooijewaard G; de Boer A; Turion PN; Cohen AF; Breimer DD; Kluft C
Thromb Haemost; 1991 Jan; 65(1):82-6. PubMed ID: 1902597
[TBL] [Abstract][Full Text] [Related]
2. DDAVP induces systemic release of urokinase-type plasminogen activator.
Levi M; ten Cate JW; Dooijewaard G; Sturk A; Brommer EJ; Agnelli G
Thromb Haemost; 1989 Sep; 62(2):686-9. PubMed ID: 2510348
[TBL] [Abstract][Full Text] [Related]
3. Plasminogen activators t-PA, u-PA and its inhibitor (PAI) in normal males and females.
Koh SC; Yuen R; Viegas OA; Chua SE; Ng BL; Sen DK; Ratnam SS
Thromb Haemost; 1991 Nov; 66(5):581-5. PubMed ID: 1803623
[TBL] [Abstract][Full Text] [Related]
4. Differences in u-PA and t-PA increase during acute exercise: relation with exercise parameters.
van den Burg PJ; Dooijewaard G; van Vliet M; Mosterd WL; Kluft C; Huisveld IA
Thromb Haemost; 1994 Feb; 71(2):236-9. PubMed ID: 8191405
[TBL] [Abstract][Full Text] [Related]
5. Comparison of t-PA and u-PA levels in maximal treadmill and deep-water running.
Ohkuwa T; Itoh H; Yamamoto T; Yamazaki Y
Prev Med; 2004 Jul; 39(1):177-81. PubMed ID: 15208000
[TBL] [Abstract][Full Text] [Related]
6. Diurnal variation of the fibrinolytic system.
Grimaudo V; Hauert J; Bachmann F; Kruithof EK
Thromb Haemost; 1988 Jun; 59(3):495-9. PubMed ID: 3142085
[TBL] [Abstract][Full Text] [Related]
7. Fibrinolysis and coagulation in patients with infectious disease and sepsis.
Philippé J; Offner F; Declerck PJ; Leroux-Roels G; Vogelaers D; Baele G; Collen D
Thromb Haemost; 1991 Mar; 65(3):291-5. PubMed ID: 1904655
[TBL] [Abstract][Full Text] [Related]
8. Depression of tissue-type plasminogen activator and enhancement of urokinase-type plasminogen activator as an expression of local inflammation.
Brommer EJ; Dooijewaard G; Dijkmans BA; Breedveld FC
Thromb Haemost; 1992 Aug; 68(2):180-4. PubMed ID: 1412164
[TBL] [Abstract][Full Text] [Related]
9. Evolution of urokinase-type plasminogen activator (u-PA) and tissue-type plasminogen activator (t-PA) in orthotopic liver transplantation (OLT).
Himmelreich G; Dooijewaard G; Breinl P; Bechstein WO; Neuhaus P; Kluft C; Riess H
Thromb Haemost; 1993 Jan; 69(1):56-9. PubMed ID: 8446939
[TBL] [Abstract][Full Text] [Related]
10. Plasminogen activators (t-PA and u-PA) and plasminogen activators inhibitors (PAI-1 and PAI-2) in some myeloproliferative syndromes.
Rość D; Kremplewska-Nalezyta E; Gadomska G; Zastawna E; Michalski A; Drewniak W
Med Sci Monit; 2000; 6(4):684-91. PubMed ID: 11208392
[TBL] [Abstract][Full Text] [Related]
11. Plasminogen activators and plasminogen activator inhibitors in liver deficiencies caused by chronic alcoholism or infectious hepatitis.
Tran-Thang C; Fasel-Felley J; Pralong G; Hofstetter JR; Bachmann F; Kruithof EK
Thromb Haemost; 1989 Sep; 62(2):651-3. PubMed ID: 2510345
[TBL] [Abstract][Full Text] [Related]
12. Fibrinolysis system in patients with bronchial asthma.
Banach-Wawrzeńczyk E; Dziedziczko A; Rość D
Med Sci Monit; 2000; 6(1):103-7. PubMed ID: 11208294
[TBL] [Abstract][Full Text] [Related]
13. Age dependence of blood fibrinolytic components and the effects of low-dose oral contraceptives on coagulation and fibrinolysis in teenagers.
Siegbahn A; Ruusuvaara L
Thromb Haemost; 1988 Dec; 60(3):361-4. PubMed ID: 3149043
[TBL] [Abstract][Full Text] [Related]
14. Inhibition in purified systems and in human plasma of chimaeric plasminogen activators consisting of the NH2-terminal region of tissue-type plasminogen activator and the COOH-terminal region of urokinase-type plasminogen activator.
Lijnen HR; Nelles L; Van Hoef B; De Cock F; Collen D
Thromb Haemost; 1988 Oct; 60(2):247-50. PubMed ID: 3146141
[TBL] [Abstract][Full Text] [Related]
15. Sensitive and specific enzyme-linked immunosorbent assay for urokinase-type plasminogen activator and its application to plasma from patients with breast cancer.
Grøndahl-Hansen J; Agerlin N; Munkholm-Larsen P; Bach F; Nielsen LS; Dombernowsky P; Danø K
J Lab Clin Med; 1988 Jan; 111(1):42-51. PubMed ID: 3121772
[TBL] [Abstract][Full Text] [Related]
16. Fibrinolysis in normal subjects--comparison between plasminogen activator inhibitor and other components of the fibrinolytic system.
Nicoloso G; Hauert J; Kruithof EK; Van Melle G; Bachmann F
Thromb Haemost; 1988 Apr; 59(2):299-303. PubMed ID: 3133812
[TBL] [Abstract][Full Text] [Related]
17. Effects of increased liver blood flow on the kinetics and dynamics of recombinant tissue-type plasminogen activator.
van Griensven JM; Huisman LG; Stuurman T; Dooijewaard G; Kroon R; Schoemaker RC; Kluft K; Cohen AF
Clin Pharmacol Ther; 1996 Nov; 60(5):504-11. PubMed ID: 8941023
[TBL] [Abstract][Full Text] [Related]
18. Potentiation by Lys-plasminogen of clot lysis by single or two chain urokinase-type plasminogen activator or tissue-type plasminogen activator.
Watahiki Y; Scully MF; Ellis V; Kakkar VV
Thromb Haemost; 1989 Jun; 61(3):502-6. PubMed ID: 2508259
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of fibrinolytic capacity in plasma during thrombolytic therapy with single (scu-PA) or two-chain urokinase type plasminogen activator (tcu-PA) by a combined assay system for urokinase type plasminogen activator antigen and function.
Wojta J; Binder BR; Huber K; Hoover RL
Thromb Haemost; 1989 Apr; 61(2):289-93. PubMed ID: 2501899
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of fibrinolytic capacity by a combined assay system for tissue-type plasminogen activator antigen and function using monoclonal anti-tissue-type plasminogen activator antibodies.
Wojta J; Turcu L; Wagner OF; Korninger C; Binder BR
J Lab Clin Med; 1987 Jun; 109(6):665-71. PubMed ID: 3108431
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
